Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 1, Pages 248-262Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01266
Keywords
-
Categories
Funding
- Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR, PRIN) [2010NRREPL_006]
- Istituto Toscano Tumori (ITT) [7197 29/12/2009]
- Ente Cassa di Risparmio di Firenze [2013.0688]
Ask authors/readers for more resources
On the basis of a previously discovered anti-alpha(v)beta(3) integrin peptidomimetic (c(AmpRGD)) and the clinically approved antiangiogenic kinase inhibitor Sunitinib, three novel dual conjugates were synthesized (compounds 1-3), featuring the covalent and robust linkage between these two active modules. In all conjugates, the ligand binding competence toward alpha(v)beta(3) (using both isolated receptors and avi63-overexpressing endothelial progenitor EP cells) and the kinase inhibitory activity (toward both isolated kinases and EPCs) remained, almost untouched and comparable to the activity of the single active units. Compounds 1-3 showed interesting antiangiogenesis properties in an in vitro tubulogenic assay; furthermore, dimeric-RGD conjugate 3 strongly inhibited in vivo angiogenesis in Matrigelylug assays in FVB mice. These results offer proof-of-concept of how the covalent conjugation of two angiogenesis-related small;modules may result in novel and stable molecules, which impair tumor-related angiogenesis with equal or even superior ability as compared to the single modules or their simple combinations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available